CSIMarket Company Name, Ticker, Customers, else..


Veracyte Inc   (NASDAQ: VCYT)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Veracyte Inc

VCYT's Fundamental analysis



Looking into Veracyte Inc growth rates, revenue grew by 11.01 % in the first quarter of 2025 from the same quarter a year ago.

Medical Laboratories industry recorded growth of revenues by 2.95 %

Veracyte Inc realized net income compared to net loss a year ago in first quarter of 2025

• More on VCYT's Growth


Veracyte Inc
current PE on trailing twelve month basis is above Medical Laboratories industry average.

Veracyte Inc PEG ratio is at -0.5 Veracyte Inc realized cash reduction of $ -0.56 per share in trailing twelve-month period.
Company
71.62
PE TTM   
Industry
-0
PE TTM    
Company's Price to Sales ratio is at 5.53.
Medical Laboratories industry's Price to Sales ratio is at 2.19.


• More on VCYT's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 518,784
 Net Income/Employee (TTM) $ 40,551
 Receivable Turnover (TTM) 8.48
 Tangible Book Value (Per Share $) 4.27

Veracyte Inc
current PE on trailing twelve month basis is above Medical Laboratories industry average.

Veracyte Inc PEG ratio is at -0.5 Veracyte Inc realized cash outflow of $ -0.56per share in trailing twelve-month period.
Company
71.62
PE TTM   
Industry
-0
PE TTM    
Company's Price to Sales ratio is at 5.53.
Medical Laboratories industry's Price to Sales ratio is at 2.19.

Veracyte Inc Price to Book Ratio is at 1.96 lower than Industry Avg. of 148.16. and higher than S&P 500 Avg. of 0.01

• More on VCYT's Valuation

•  Market Capitalization (Millions $) 2,340
•  Shares Outstanding (Millions) 80
•  Employees 815
•  Revenues (TTM) (Millions $) 423
•  Net Income (TTM) (Millions $) 33
•  Cash Flow (TTM) (Millions $) -45
•  Capital Exp. (TTM) (Millions $) -11
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 518,784
•  Net Income/Employee(TTM) $ 40,551
•  Receivable Turnover Ratio (TTM) 8.48
•  Tangible Book Value (Per Share $) 4.27

•  Market Capitalization (Millions $) 2,340
•  Shares Outstanding (Millions) 80
•  Employees 815
•  Revenues (TTM) (Millions $) 423
•  Net Income (TTM) (Millions $) 33
•  Cash Flow (TTM) (Millions $) -45
•  Capital Exp. (TTM) (Millions $) -11


    VCYT's Profitability Comparisons
Veracyte Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 2.7 % from 4.08 % in IV. Quarter.

Veracyte Inc net profit margin of 6.55 % is currently ranking no. 6 in Medical Laboratories industry, ranking no. 88 in Healthcare sector and number 1129 in S&P 500.


Profitability by Segment
Reportable Segment 69.46 %
Total 6.55 %



  Ratio
•   Capital Ratio (MRQ) 5.8
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.33
•  Asset Turnover Ratio (TTM) 0.33
•  Inventory Turnover Ratio (TTM) 5.42



Veracyte Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 2.7 % from 4.08 % in IV. Quarter.

Veracyte Inc net profit margin of 6.55 % is currently ranking no. 6 in Medical Laboratories industry, ranking no. 88 in Healthcare sector and number 1129 in S&P 500.

• More on VCYT's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com